Peptide News 2026: Global Market Surpasses $65B, Driven by GLP-1 Innovation and 12.5% CAGR Growth
Title: Peptide News 2026: $65B Market Driven by GLP-1 Innovation & 12.5% CAGR Abstract: The global peptide market surpasses $65 billion in 2026, propelled by GLP-1 innovation and a 12.5% CAGR. This growth reshapes industry trends, with branded therapeutics (e.g., semaglutide) dominating over generics. Key technical advantages include high target specificity, while drawbacks involve poor oral bioavailability and stability. Product comparisons highlight purity (>98% HPLC) and peptide length (2-50 amino acids) as critical parameters. Applications expand from metabolic disorders to oncology. Brand status favors FDA/EMA-certified manufacturers. Logistics require cold-chain compliance (-20°C). Selection criteria prioritize third-party COAs, GMP factory audits, and batch consistency. Industry outlook remains robust, driven by obesity and anti-aging demand.